GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Quality Rank

MDXXF (Pharmala Biotech Holdings) Quality Rank


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Pharmala Biotech Holdings Quality Rank Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings Business Description

Traded in Other Exchanges
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.